IL128317A - תכשיר המכיל מופירוצין וכלורהקסידין - Google Patents
תכשיר המכיל מופירוצין וכלורהקסידיןInfo
- Publication number
- IL128317A IL128317A IL12831797A IL12831797A IL128317A IL 128317 A IL128317 A IL 128317A IL 12831797 A IL12831797 A IL 12831797A IL 12831797 A IL12831797 A IL 12831797A IL 128317 A IL128317 A IL 128317A
- Authority
- IL
- Israel
- Prior art keywords
- weight
- chlorhexidine
- composition
- mupirocin
- acceptable salt
- Prior art date
Links
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960003128 mupirocin Drugs 0.000 title claims abstract description 27
- 229930187697 mupirocin Natural products 0.000 title claims abstract description 26
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229960003260 chlorhexidine Drugs 0.000 title claims abstract description 22
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 title claims abstract 5
- 239000000203 mixture Substances 0.000 title claims description 48
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- -1 salt ester Chemical class 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 208000035143 Bacterial infection Diseases 0.000 abstract description 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
- HAXVBVDETFUQGV-LNQHITRNSA-L mupirocin calcium (anhydrous) Chemical compound [Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 HAXVBVDETFUQGV-LNQHITRNSA-L 0.000 description 23
- 239000002674 ointment Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 7
- 150000002334 glycols Chemical class 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 159000000007 calcium salts Chemical class 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 229940047652 ear drops Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- FBPFZTCFMRRESA-NQAPHZHOSA-N Sorbitol Polymers OCC(O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-NQAPHZHOSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940028420 bactroban Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229930194369 pseudomonic acid Natural products 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9616208.6A GB9616208D0 (en) | 1996-08-01 | 1996-08-01 | Novel Compounds |
| PCT/EP1997/004165 WO1998005313A1 (en) | 1996-08-01 | 1997-07-29 | Composition comprising mupirocin and chlorhexidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL128317A0 IL128317A0 (en) | 2000-01-31 |
| IL128317A true IL128317A (he) | 2001-08-08 |
Family
ID=10797878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12831797A IL128317A (he) | 1996-08-01 | 1997-07-29 | תכשיר המכיל מופירוצין וכלורהקסידין |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6214866B1 (he) |
| EP (1) | EP0921791B1 (he) |
| JP (1) | JP2000517294A (he) |
| KR (1) | KR20000029678A (he) |
| CN (1) | CN1231606A (he) |
| AR (1) | AR008797A1 (he) |
| AT (1) | ATE207350T1 (he) |
| AU (1) | AU708688B2 (he) |
| BR (1) | BR9710899A (he) |
| CA (1) | CA2262430A1 (he) |
| CZ (1) | CZ29199A3 (he) |
| DE (1) | DE69707691T2 (he) |
| ES (1) | ES2163186T3 (he) |
| GB (1) | GB9616208D0 (he) |
| IL (1) | IL128317A (he) |
| NO (1) | NO990440L (he) |
| NZ (1) | NZ333896A (he) |
| PL (1) | PL331423A1 (he) |
| TR (1) | TR199900211T2 (he) |
| WO (1) | WO1998005313A1 (he) |
| ZA (1) | ZA976791B (he) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| AU2004290580A1 (en) * | 2003-11-17 | 2005-06-02 | Braintree Laboratories, Inc. | Therapeutic PEG solution concentrate |
| US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
| US20060051384A1 (en) | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
| US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| WO2006099325A2 (en) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methods of treating ear infections |
| BRPI0608691A2 (pt) * | 2005-03-10 | 2010-12-07 | 3M Innovative Properties Company | composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição |
| BRPI0608690B8 (pt) * | 2005-03-10 | 2021-05-25 | 3M Innovative Properties Co | uso de uma composição antimicrobiana |
| EP2091324B1 (en) | 2006-10-27 | 2016-12-28 | 3M Innovative Properties Company | Antimicrobial compositions |
| US20110097372A1 (en) * | 2009-10-26 | 2011-04-28 | Rucinski Paul J | Devices, methods, and compositions for controlling infections |
| SE533425C2 (sv) * | 2008-07-07 | 2010-09-21 | Ambria Dermatology Ab | Antimikrobiell sammansättning |
| CA2778081A1 (en) * | 2009-10-26 | 2011-05-12 | Innovation Technologies, Inc. | Devices, methods, and composition for controlling infections |
| DE102012215511A1 (de) | 2012-08-31 | 2014-06-12 | Schülke & Mayr GmbH | Verfahren zur Herstellung einer Bispyridiniumalkan enthaltenden halbfesten Zubereitung |
| WO2017095352A1 (en) | 2015-12-01 | 2017-06-08 | Ataturk Universitesi Bilimsel Arastirma Projeleri Birimi | Use of wax, olive oil, butter mixture and/ or its combination with varying ratios of boron and/ or derivatives thereof, in treatment of wounds, burns, and skin diseases |
| EP3452093B1 (en) * | 2016-05-06 | 2021-04-28 | Sacsh Corp. | Ophthalmic compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758686A (en) | 1971-12-07 | 1973-09-11 | American Cyanamid Co | Method of using steroid acetonides |
| US4122158A (en) | 1976-09-23 | 1978-10-24 | Alza Corporation | Topical therapeutic preparations |
| CA1196284A (en) | 1982-05-28 | 1985-11-05 | Joshua Oduro-Yeboah | Pharmaceutical formulations |
| EP0128228B1 (de) | 1983-06-08 | 1988-01-07 | Ibm Deutschland Gmbh | Verfahren und Anordnung zur Erzeugung von Impulsen beliebiger Zeitrelation innerhalb unmittelbar aufeinanderfolgender Impulsintervalle mit sehr hoher Genauigkeit und zeitlicher Auflösung |
| GB8415579D0 (en) | 1984-06-19 | 1984-07-25 | Beecham Group Plc | Compounds |
| IT1202193B (it) | 1985-10-31 | 1989-02-02 | Pico Glass Spa | Cornice porta-immagine |
| GB8530796D0 (en) | 1985-12-13 | 1986-01-22 | Beecham Group Plc | Pharmaceutical composition |
| IE59628B1 (en) | 1986-06-26 | 1994-03-09 | Beecham Group Plc | Treatment of fungal infections |
| US4847068A (en) | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
| GB9507825D0 (en) * | 1995-04-18 | 1995-05-31 | Wet Pieter M De | Method of treatment |
-
1996
- 1996-08-01 GB GBGB9616208.6A patent/GB9616208D0/en active Pending
-
1997
- 1997-07-29 CN CN97198188A patent/CN1231606A/zh active Pending
- 1997-07-29 DE DE69707691T patent/DE69707691T2/de not_active Expired - Fee Related
- 1997-07-29 EP EP97934558A patent/EP0921791B1/en not_active Expired - Lifetime
- 1997-07-29 KR KR1019997000756A patent/KR20000029678A/ko not_active Withdrawn
- 1997-07-29 ES ES97934558T patent/ES2163186T3/es not_active Expired - Lifetime
- 1997-07-29 NZ NZ333896A patent/NZ333896A/en unknown
- 1997-07-29 CZ CZ99291A patent/CZ29199A3/cs unknown
- 1997-07-29 AT AT97934558T patent/ATE207350T1/de not_active IP Right Cessation
- 1997-07-29 BR BR9710899-5A patent/BR9710899A/pt not_active Application Discontinuation
- 1997-07-29 WO PCT/EP1997/004165 patent/WO1998005313A1/en not_active Ceased
- 1997-07-29 CA CA002262430A patent/CA2262430A1/en not_active Abandoned
- 1997-07-29 IL IL12831797A patent/IL128317A/he not_active IP Right Cessation
- 1997-07-29 TR TR1999/00211T patent/TR199900211T2/xx unknown
- 1997-07-29 AU AU37717/97A patent/AU708688B2/en not_active Ceased
- 1997-07-29 PL PL97331423A patent/PL331423A1/xx unknown
- 1997-07-29 JP JP10507583A patent/JP2000517294A/ja active Pending
- 1997-07-29 US US09/230,756 patent/US6214866B1/en not_active Expired - Fee Related
- 1997-07-30 ZA ZA976791A patent/ZA976791B/xx unknown
- 1997-07-31 AR ARP970103481A patent/AR008797A1/es not_active Application Discontinuation
-
1999
- 1999-01-29 NO NO990440A patent/NO990440L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69707691D1 (de) | 2001-11-29 |
| NZ333896A (en) | 2000-06-23 |
| IL128317A0 (en) | 2000-01-31 |
| GB9616208D0 (en) | 1996-09-11 |
| BR9710899A (pt) | 2000-01-11 |
| CA2262430A1 (en) | 1998-02-12 |
| KR20000029678A (ko) | 2000-05-25 |
| NO990440D0 (no) | 1999-01-29 |
| ES2163186T3 (es) | 2002-01-16 |
| AU708688B2 (en) | 1999-08-12 |
| EP0921791A1 (en) | 1999-06-16 |
| CZ29199A3 (cs) | 1999-07-14 |
| DE69707691T2 (de) | 2002-08-01 |
| US6214866B1 (en) | 2001-04-10 |
| JP2000517294A (ja) | 2000-12-26 |
| CN1231606A (zh) | 1999-10-13 |
| WO1998005313A1 (en) | 1998-02-12 |
| ATE207350T1 (de) | 2001-11-15 |
| EP0921791B1 (en) | 2001-10-24 |
| ZA976791B (en) | 1999-02-09 |
| TR199900211T2 (xx) | 1999-03-22 |
| NO990440L (no) | 1999-01-29 |
| AU3771797A (en) | 1998-02-25 |
| PL331423A1 (en) | 1999-07-19 |
| AR008797A1 (es) | 2000-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0921791B1 (en) | Composition comprising mupirocin and chlorhexidine | |
| US4524075A (en) | Pharmaceutical formulations containing pseudomonic acid | |
| US4474753A (en) | Topical drug delivery system utilizing thermosetting gels | |
| WO1992004016A1 (en) | Pharmaceutical composition of florfenicol | |
| WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| CA1236456A (en) | Silver pseudomonate | |
| AU707220B2 (en) | Pharmaceutical composition for parenteral application containing an indole-carboxylic acid | |
| EP0302836B1 (en) | Pharmaceutical compositions for topical use containing miocamycin | |
| US5510390A (en) | Anti-hypertensive composition and methods of treatment | |
| MXPA99001136A (en) | Composition comprising mupirocin and chlorhexidine | |
| AP9801235A0 (en) | Erythromycin derivatives. | |
| US5985291A (en) | Method of treating infections using mupirocin chlorhexidene | |
| EP0238207B1 (en) | Bactericidal mixtures | |
| SK5682000A3 (en) | Compositions containing thiamphenicol and diclofenac | |
| HUP9903088A2 (hu) | Mupirocint és klórhexidint tartalmazó gyógyszerkészítmény | |
| EP0384722B1 (en) | Chemical compositions | |
| EP0154484A2 (en) | 7-D-Mandelamido-3-(1-sulfomethyltetrazol-5-YL)Thiomethyl-3-cephem-4-carboxylic acid monosodium salt | |
| JPS63264418A (ja) | 安定化された眼科用組成物 | |
| JPH0348886B2 (he) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |